[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559690":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":10,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention group",null,"patients were treated with alirocumab 75mg combined with statin ± ezetimibe",[13],"Drug: alirocumab 75mg\u002F2week",{"label":15,"type":10,"description":16,"interventionNames":17},"control group","patients were treated with statin ± ezetimibe only",[18],"Drug: statin ± ezetimibe",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","alirocumab 75mg\u002F2week","patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"statin ± ezetimibe","patients will be censored at initiation of alirocumab during the follow up visit",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Dandan Li, Dr.","CONTACT","+86 13810545564","lidandan5564@163.com",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":53,"email":34},"Dandan Li, MD","13810545564","86",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Yun Dai Chen","professor",[59],{"name":60,"class":61},"Sanofi","INDUSTRY","100559690","retrospective-analysis-of-the-effect-of-in-hospital-initiation-of-pcsk9i-on-clinical-outcomes-in-chinese-acs-patients-100559690",false,"NCT06567418","Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients","Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients: A Database-based Retrospective Analysis","Inclusion Criteria:\n\n* Patients diagnosed with Acute Coronary Syndrome (ACS) upon hospital admission.\n* Patients aged 18 years or older.\n* Patients who received Alirocumab 75 mg in combination with statin therapy ± Ezetimibe as the intervention group, and those treated exclusively with statin therapy ± Ezetimibe as the control group, either during hospitalization or at discharge.\n* Patients with at least one follow-up record.\n\nExclusion Criteria:\n\n* Patients who received Evolocumab treatment at any time.\n* Patients who received Inclisiran treatment at any time.","ALL","18 Years",{"count":72,"type":73},10000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ± ezetimibe on major cardiovascular events (MACE) in Chinese ACS patients. The main question it aims to answer is:\n\nwhether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting.\n\nData from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023. Patients diagnosed with STEMI, NSTEMI or UA at admission were identified at the first step. Then, for intervention group, patients who received alirocumab 75mg combined with statin ± ezetimibe during the ACS hospitalization (including the discharge date) will be included; for control group, patients who received statin ± ezetimibe during the ACS hospitalization will be included. All enrolled patients were required to have at least one documented follow-up visit.",[77],"Acute Coronary Syndrome","2024-08-20",{"date":80,"type":81},"2024-08-22","ACTUAL",{"date":83,"type":81},"2024-08-01",{"date":85,"type":73},"2025-01-31",{"name":56,"class":6},1]